Modality
ADC
MOA
PD-L1i
Target
GIP-R
Pathway
Amyloid
PAHRBMDS
Development Pipeline
Preclinical
~Apr 2017
→ ~Jul 2018
Phase 1
~Oct 2018
→ ~Jan 2020
Phase 2
~Apr 2020
→ ~Jul 2021
Phase 3
~Oct 2021
→ ~Jan 2023
NDA/BLA
Apr 2023
→ Jul 2025
NDA/BLACurrent
NCT08960559
1,997 pts·RB
2023-04→2025-07·Terminated
1,997 total pts1 indication
Approved
CompletedCurrentUpcoming
Catalysts (1)
2025-07-099mo agoPh3 Readout· RB
Trial Timeline
Q2Q3Q42024Q2Q3Q42025Q2Q3
NDA/BLA
Termina…
Catalysts
Ph3 Readout
2025-07-09 · 9mo ago
RB
Terminated|StartCompletionToday
Trials (1)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT08960559 | NDA/BLA | RB | Terminated | 1997 | ACR20 |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| PFE-1085 | Pfizer | Preclinical | FXIa | |
| JNJ-5094 | Johnson & Johnson | Phase 2/3 | GIP-R | |
| RHH-3592 | Roche | Phase 1/2 | GIP-R | |
| Rilulemzoparlimab | Novartis | Phase 2/3 | KRASG12D | |
| AZN-5978 | AstraZeneca | Phase 2/3 | GIP-R | |
| SNY-9600 | Sanofi | NDA/BLA | B7-H3 | |
| Ivotuximab | GSK | NDA/BLA | GIP-R | |
| Nirafutibatinib | Bayer | Phase 2 | WRN | |
| Motainavolisib | Amgen | NDA/BLA | CD47 | |
| Elrarapivir | Regeneron | Phase 1 | GIP-R |